ENGAGE-501: Phase 2 Study Investigating the Role of Epigenetic Therapy with Entinostat (SNDX-275) In Relapsed and Refractory Hodgkin's Lymphoma (HL), Interim Results

被引：0
|
作者：
Younes, Anas [1 ]
Hernandez, Francisco [2 ,3 ]
Bociek, R. Gregory [4 ]
Kasamon, Yvette L. [5 ]
Lee, Peter [6 ]
Gore, Lia [7 ]
Buglio, Daniela [8 ]
Copeland, Amanda [9 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Clin Invest & Translat Res Dept Lymphoma Myeloma, Houston, TX 77030 USA
[2] Roswell Pk Canc Inst, Dept Med Oncol, Buffalo, NY 14263 USA
[3] Roswell Pk Canc Inst, Dept Immunol Canc Cell Ctr, Buffalo, NY 14263 USA
[4] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE USA
[5] Johns Hopkins Univ, Baltimore, MD USA
[6] Tower Canc Res Fdn, Beverly Hills, CA USA
[7] Univ Colorado Canc Ctr, Aurora, CO USA
[8] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[9] Univ Texas Houston, MD Anderson Canc Ctr Hymphoma Myeloma, Houston, TX USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1614 / 1615
页数：2
相关论文
共 50 条
  • [31] Interim results of a phase I/II study of ocrelizumab, a new humanised Anti-CD20 antibody in patients with relapsed/refractory follicular non-hodgkin's lymphoma
    Morschhauser, Franck
    Marlton, Paula
    Vitolo, Umberto
    Linden, Ola
    Seymour, John
    Crump, Michael
    Coiffier, Bertrand
    Pulsoni, Alessandro
    Belch, Andrew
    Lerch, Erika
    Kimby, Eva
    Arnljots, Kristina
    Wassner, Elisabeth
    Mendila, Myriam
    BLOOD, 2007, 110 (11) : 199A - 199A
  • [32] A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results
    Jacobsen, Eric D.
    Advani, Ranjana H.
    Oki, Yasuhiro
    Sharman, Jeff
    Horwitz, Steven M.
    Forero-Torres, Andres
    O'Connor, Owen A.
    Shustov, Andrei R.
    Siddiqi, Tanya
    Grove, Laurie E.
    Bartlett, Nancy L.
    BLOOD, 2012, 120 (21)
  • [33] A Lysa Phase II Study of Oral JAK1/2 Inhibitor Ruxolitinib in Advanced Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)
    Van Den Neste, Eric W.
    Andre, Marc
    Gastinne, Thomas
    Stamatoullas, Aspasia
    Haioun, Corinne
    Belhabri, Amine
    Reman, Oumedaly
    Casasnovas, Olivier
    Ghesquieres, Herve
    Verhoef, Gregor
    Claessen, Marie-Jose
    Poirel, Helene A.
    Copin, Marie-Christine
    Dubois, Romain
    Vandenberghe, Peter
    Stoian, Ioanna-Andrea
    Cottereau, Anne Segolene
    Knoops, Laurent
    Morschhauser, Franck
    BLOOD, 2016, 128 (22)
  • [34] Tislelizumab (BGB-A317) for Relapsed/Refractory Classical Hodgkin Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study
    Song, Yuqin
    Gao, Quanli
    Zhang, Huilai
    Fan, Lei
    Zhou, Jianfeng
    Zou, Dehui
    Li, Wei
    Yang, Haiyan
    Liu, Ting
    Wang, Quanshun
    Lv, Fangfang
    Yang, Yu
    Guo, Haiyi
    Yang, Liudi
    Elstrom, Rebecca
    Huang, Jane
    Novotny, William
    Wei, Vivian
    Zhu, Jun
    BLOOD, 2018, 132
  • [35] A Phase 2 Study of Nivolumab for Relapsed/Refractory Multiple Myeloma or Non-Hodgkin Lymphoma Following CAR-T Therapy
    Banerjee, Rahul
    Lynch, Ryan C.
    Wu, Qian
    Simon, Sylvain
    Ujjani, Chaitra S.
    Till, Brian G.
    Wuliji, Natalie
    Gausman, Daria
    Dizon, Joshua
    Kwok, Mary L.
    Lee, Sarah S.
    Silbermann, Rebecca
    Medvedova, Eva
    Maloney, David G.
    Ramos, Jorge Daniel
    Shadman, Mazyar
    Gauthier, Jordan
    Turtle, Cameron J.
    Gopal, Ajay K.
    Green, Damian J.
    Riddell, Stanley R.
    Cowan, Andrew J.
    BLOOD, 2023, 142
  • [36] Phase I/II study of brentuximab vedotin in pediatric patients (pts) with relapsed or refractory (RR) Hodgkin lymphoma (HL) or systemic anaplastic large-cell lymphoma (sALCL): Interim phase (ph) I safety data
    Neville, Kathleen
    Gore, Lia
    Mauz-Koerholz, Christine
    Rosolen, Angelo
    Landman-Parker, Judith
    de Toledo, Jose Sanchez
    Beishuizen, Auke
    Franklin, Anna Rachel Keating
    Fasanmade, Adedigbo
    Wang, Jingyuan
    Huebner, Dirk
    Locatelli, Franco
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [37] PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA OR SYSTEMIC ANAPLASTIC LARGE-CELL LYMPHOMA: INTERIM PHASE 1 SAFETY AND PHARMACOKINETIC DATA
    Locatelli, F.
    Gore, L.
    Mauz-Koerholz, C.
    Rosolen, A.
    Landman-Parker, J.
    de Toledo, J.
    Beishuizen, A.
    Fasanmade, A.
    Wang, J.
    Fingert, H.
    Labotka, R.
    Neville, K.
    HAEMATOLOGICA, 2013, 98 : 68 - 68
  • [38] Updated Results of a Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
    Christian, Beth A.
    Kuruvilla, John G.
    Smith, Sonali M.
    Porcu, Pierluigi
    Maddocks, Kami J.
    Ruppert, Amy S.
    Byrd, John C.
    Grever, Michael R.
    Blum, Kristie A.
    BLOOD, 2015, 126 (23)
  • [39] Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study
    Qualls, David
    Noy, Ariela
    Straus, David
    Matasar, Matthew
    Moskowitz, Craig
    Seshan, Venkatraman
    Dogan, Ahmet
    Salles, Gilles
    Younes, Anas
    Zelenetz, Andrew D.
    Batlevi, Connie Lee
    LEUKEMIA & LYMPHOMA, 2023, 64 (03) : 738 - 741
  • [40] Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin's and aggressive non-Hodgkin's lymphoma -: Results of a multicenter phase-II study.
    Josting, A
    Rudolph, C
    Mapara, M
    Ko, Y
    Söhngen, D
    Dorken, B
    Diehl, V
    Engert, A
    BLOOD, 2001, 98 (11) : 681A - 681A
12345